Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 May 23

PMID 35603224

Authors

Yamei Duan

Xiongfeng Pan

Jiayou Luo

Xiang Xiao

Jingya Li

Prince L Bestman

Miyang Luo

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory cytokines have been considered to be significant factors contributing to the development and progression of non-alcoholic fatty liver disease (NAFLD). However, the role of inflammatory cytokines in NAFLD remains inconclusive.

Objective: This study aimed to evaluate the association between inflammatory cytokines and NAFLD.

Methods: PubMed, Web of Science, the Cochrane Library, and EMBASE databases were searched until 31 December 2021 to identify eligible studies that reported the association of inflammatory cytokine with NAFLD and its subtypes. We pooled odds ratios (ORs) and hazard risk (HRs) with 95% confidence intervals (CIs) and conducted heterogeneity tests. Sensitivity analysis and analysis for publication bias were also carried out.

Results: The search in the databases identified 51 relevant studies that investigated the association between 19 different inflammatory cytokines and NAFLD based on 36,074 patients and 47,052 controls. The results of the meta-analysis showed significant associations for C-reactive protein (CRP), interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and intercellular adhesion molecule-1 (ICAM-1) with NAFLD (ORs of 1.41, 1.08, 1.50, 1.15 and 2.17, respectively). In contrast, we observed non-significant associations for interferon-γ (IFN-γ), insulin-like growth factor (IGF-II), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12 (IL-12), monocyte chemoattractant protein-1(MCP-1), and transforming growth factor-β (TGF-β) with NAFLD. Our results also showed that CRP, IL-1β, and TNF-α were significantly associated with non-alcoholic steatohepatitis (NASH) and hepatic fibrosis.

Conclusions: Our results indicated that increased CRP, IL-1β, IL-6, TNF-α, and ICAM-1 concentrations were significantly associated with increased risks of NAFLD. These inflammatory mediators may serve as biomarkers for NAFLD subjects and expect to provide new insights into the aetiology of NAFLD as well as early diagnosis and intervention.

Citing Articles

The Impact of Steatotic Liver Disease on Cytokine and Chemokine Kinetics During Sepsis.

Vrsaljko N, Radmanic Matotek L, Zidovec-Lepej S, Vince A, Papic N Int J Mol Sci. 2025; 26(5).

PMID: 40076848 PMC: 11900930. DOI: 10.3390/ijms26052226.

Dapagliflozin attenuates metabolic dysfunction-associated steatotic liver disease by inhibiting lipid accumulation, inflammation and liver fibrosis.

Fan X, Wang Y, Wang Y, Duan H, Du Y, Pan T BMC Pharmacol Toxicol. 2025; 26(1):59.

PMID: 40075451 PMC: 11905655. DOI: 10.1186/s40360-025-00898-z.

Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017-2018.

Liang B, Qiu X, Huang J, Lu Y, Shen H, Ma J Sci Rep. 2025; 15(1):4029.

PMID: 39900651 PMC: 11791041. DOI: 10.1038/s41598-025-88685-y.

Association between sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis.

Pirahesh K, Zarrinnia A, Nikniaz L, Nikniaz Z Prev Med Rep. 2025; 50:102968.

PMID: 39897736 PMC: 11783128. DOI: 10.1016/j.pmedr.2025.102968.

Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model.

Gillet R, Cerda-Drago T, Branes M, Valenzuela R Int J Mol Sci. 2025; 26(2).

PMID: 39859279 PMC: 11766071. DOI: 10.3390/ijms26020564.

References

Pierantonelli I, Svegliati-Baroni G . Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2018; 103(1):e1-e13. DOI: 10.1097/TP.0000000000002480. View

Tabuchi M, Tomioka K, Kawakami T, Murakami Y, Hiramatsu M, Itoshima T . Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol (Tokyo). 2011; 56(5):271-8. DOI: 10.3177/jnsv.56.271. View

Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S . High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007; 42(7):573-82. DOI: 10.1007/s00535-007-2060-x. View

Ceccarelli S, Panera N, Mina M, Gnani D, De Stefanis C, Crudele A . LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget. 2015; 6(39):41434-52. PMC: 4747165. DOI: 10.18632/oncotarget.5163. View

Kumar R, Porwal Y, Dev N, Kumar P, Chakravarthy S, Kumawat A . Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. J Family Med Prim Care. 2020; 9(1):390-394. PMC: 7014887. DOI: 10.4103/jfmpc.jfmpc_887_19. View

Nagai H, Matsumaru K, Feng G, Kaplowitz N . Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology. 2002; 36(1):55-64. DOI: 10.1053/jhep.2002.33995. View

Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Perez-Ayuso R . Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2008; 29(1):82-8. DOI: 10.1111/j.1478-3231.2008.01823.x. View

Huang J, Hao C, Li Z, Wang L, Jiang J, Tang W . Polymorphism Impacts Proinflammatory Cytokine Levels, Survival, and Transplant-Related Mortality After Hematopoietic Stem Cell Transplantation in Adult Patients Receiving Busulfan-Based Conditioning Regimens. Front Pharmacol. 2021; 11:563321. PMC: 7770105. DOI: 10.3389/fphar.2020.563321. View

El-Derany M . Polymorphisms in Interleukin 13 Signaling and Interacting Genes Predict Advanced Fibrosis and Hepatocellular Carcinoma Development in Non-Alcoholic Steatohepatitis. Biology (Basel). 2020; 9(4). PMC: 7236020. DOI: 10.3390/biology9040075. View

10.

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

11.

Mu W, Cheng X, Liu Y, Lv Q, Liu G, Zhang J . Potential Nexus of Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Insulin Resistance Between Hepatic and Peripheral Tissues. Front Pharmacol. 2019; 9:1566. PMC: 6339917. DOI: 10.3389/fphar.2018.01566. View

12.

Ajmal M, Yaccha M, Malik M, Rabbani M, Ahmad I, Isalm N . Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α. Indian Heart J. 2015; 66(6):574-9. PMC: 4310973. DOI: 10.1016/j.ihj.2014.08.006. View

13.

Satapathy S, Sanyal A . Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015; 35(3):221-35. DOI: 10.1055/s-0035-1562943. View

14.

Viglino D, Jullian-Desayes I, Minoves M, Aron-Wisnewsky J, Leroy V, Zarski J . Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.01923-2016. View

15.

de Carvalho Ribeiro M, Szabo G . Role of the Inflammasome in Liver Disease. Annu Rev Pathol. 2021; 17:345-365. PMC: 10501045. DOI: 10.1146/annurev-pathmechdis-032521-102529. View

16.

Al Rifai M, Silverman M, Nasir K, Budoff M, Blankstein R, Szklo M . The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015; 239(2):629-33. PMC: 4406399. DOI: 10.1016/j.atherosclerosis.2015.02.011. View

17.

Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K . High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol. 2009; 44(4):313-21. DOI: 10.1007/s00535-009-0002-5. View

18.

Holterman A, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A . Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity (Silver Spring). 2013; 21(3):591-7. DOI: 10.1002/oby.20174. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Qiu T, Pei P, Yao X, Jiang L, Wei S, Wang Z . Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway. Cell Death Dis. 2018; 9(10):946. PMC: 6148242. DOI: 10.1038/s41419-018-1004-0. View